Agenus botensilimab/balstilimab data update in sarcomas selected for oral presentation at esmo 2023

Lexington, mass.--(business wire)--immuno-oncology leader, agenus inc. (“agenus”) (nasdaq: agen), today announced a data update from the phase 1 expansion cohort of botensilimab (multifunctional ctla-4 antibody) in combination with balstilimab (pd-1 antibody) for patients with advanced, refractory sarcomas has been selected for an oral presentation at the upcoming esmo congress, to be held october 20 – 24, 2023 in madrid, spain. presentation details: abstract title: efficacy and safety of boten.
AGEN Ratings Summary
AGEN Quant Ranking